ArticleEvidence-based complementary and alternative medicine : eCAM2017
Efficacy of Juzentaihoto for Tumor Immunotherapy in B16 Melanoma Metastasis Model.
Article in Evidence-based complementary and alternative medicine : eCAM, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Natural compounds as immune checkpoint inhibitors in melanoma: a systematic review.Naunyn-Schmiedeberg's archives of pharmacology · 2026Pooled it
- Traditional Herbal Medicine, Sipjeondaebo-Tang, for Cancer-Related Fatigue: A Randomized, Placebo-Controlled, Preliminary Study.Integrative cancer therapiesTrial
- Synergistic effects of elranatamab and Juzentaihoto, Japanese traditional herbal medicine, in triple-class-exposed relapsed/refractory multiple myeloma with extramedullary disease: a case report.International journal of hematology · 2026Article
- Advancement ofChinese herbal medicines · 2026Review
- Immunomodulatory Effects of Juzentaihoto on Fas-Mediated Apoptosis: Insights from Cancer Patients and In Vitro Models.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Traditional Chinese medicine in the era of immune checkpoint inhibitor: theory, development, and future directions.Chinese medicine · 2023Review
- CD8Evidence-based complementary and alternative medicine : eCAM · 2023Article
- Neurological adverse events associated with PD-1/PD-L1 immune checkpoint inhibitors.Frontiers in neuroscience · 2023Review
- Combination therapy of Juzentaihoto and mesenchymal stem cells attenuates liver damage and regresses fibrosis in mice.Regenerative therapy · 2021Article
- PD-1 Blockade on Tumor Microenvironment-Resident ILC2s Promotes TNF-α Production and Restricts Progression of Metastatic Melanoma.Frontiers in immunology · 2021Article
- Kampo Formulae for the Treatment of Neuropathic Pain ∼ Especially the Mechanism of Action ofFrontiers in molecular neuroscience · 2021Review
- Research Status and Molecular Mechanism of the Traditional Chinese Medicine and Antitumor Therapy Combined Strategy Based on Tumor Microenvironment.Frontiers in immunology · 2020Review
- Article
- Article
- Efficacy and Safety of Sipjeondaebo-Tang for Anorexia in Patients with Cancer: A Pilot, Randomized, Double-Blind, Placebo-Controlled Trial.Evidence-based complementary and alternative medicine : eCAM · 2017Article
- Japanese Kampo Medicine Juzentaihoto Enhances Antitumor Immunity in CD1dIntegrative cancer therapiesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.